Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

EMERYVILLE, Calif., Feb. 7, 2024 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the pricing of its upsized initial…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks